BDBM72327 MLS000394760::N-[4-[(E)-3-(3-hydroxy-4-methoxy-phenyl)acryloyl]phenyl]-4-methyl-benzenesulfonamide::N-[4-[(E)-3-(3-hydroxy-4-methoxyphenyl)-1-oxoprop-2-enyl]phenyl]-4-methylbenzenesulfonamide::N-[4-[(E)-3-(3-hydroxy-4-methoxyphenyl)prop-2-enoyl]phenyl]-4-methylbenzenesulfonamide::N-[4-[(E)-3-(4-methoxy-3-oxidanyl-phenyl)prop-2-enoyl]phenyl]-4-methyl-benzenesulfonamide::SMR000242876::cid_15945303

SMILES COc1ccc(\C=C\C(=O)c2ccc(NS(=O)(=O)c3ccc(C)cc3)cc2)cc1O

InChI Key InChIKey=JMYORYBWIOHASB-UHFFFAOYSA-N

Data  1 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 72327   

TargetSodium channel protein type 10 subunit alpha(Human)
Glaxosmithkline Intellectual Property Development

US Patent
LigandChemical structure of BindingDB Monomer ID 72327BDBM72327(2,8,9-Trifluoro-3-(trifluoromethyl)-10,11,12,13-te...)
Affinity DataIC50: 7.94nMAssay Description:Keywords: Heat Shock Factor-1 (HSF-1), Stress Response, MG132, NIH3T3, Luminescence Assay Overview: Modified NIH3T3, transformed to express firefly...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/16/2026
Entry Details US Patent